PMID- 33441417
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 2052-4897 (Electronic)
IS  - 2052-4897 (Linking)
VI  - 9
IP  - 1
DP  - 2021 Jan
TI  - Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with 
      type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND 
      Registry).
LID - 10.1136/bmjdrc-2020-001787 [doi]
LID - e001787
AB  - INTRODUCTION: Given an increasing use of dipeptidyl peptidase-4 (DPP-4) 
      inhibitors to treat patients with type 2 diabetes mellitus in the real-world 
      setting, we conducted a prospective observational study (Japan-based Clinical 
      Research Network for Diabetes Registry: J-BRAND Registry) to elucidate the safety 
      and efficacy profile of long-term usage of alogliptin. RESEARCH DESIGN AND 
      METHODS: We registered 5969 patients from April 2012 through September 2014, who 
      started receiving alogliptin (group A) or other classes of oral hypoglycemic 
      agents (OHAs; group B), and were followed for 3 years at 239 sites nationwide. 
      Safety was the primary outcome. Symptomatic hypoglycemia, pancreatitis, skin 
      disorders of non-extrinsic origin, severe infections, and cancer were collected 
      as major adverse events (AEs). Efficacy assessment was the secondary outcome and 
      included changes in hemoglobin A1c (HbA1c), fasting blood glucose, fasting 
      insulin and urinary albumin. RESULTS: Of the registered, 5150 (group A: 3395 and 
      group B: 1755) and 5096 (3358 and 1738) were included for safety and efficacy 
      analysis, respectively. Group A patients mostly (>90%) continued to use 
      alogliptin. In group B, biguanides were the primary agents, while DPP-4 
      inhibitors were added in up to ~36% of patients. The overall incidence of AEs was 
      similar between the two groups (42.7% vs 42.2%). Kaplan-Meier analysis revealed 
      the incidence of cancer was significantly higher in group A than in group B (7.4% 
      vs 4.8%, p=0.040), while no significant incidence difference was observed in the 
      individual cancer. Multivariate Cox regression analysis revealed that the 
      imbalanced patient distribution (more elderly patients in group A than in group 
      B), but not alogliptin usage per se, contributed to cancer development. The 
      incidence of other major AE categories was with no between-group difference. 
      Between-group difference was not detected, either, in the incidence of 
      microvascular and macrovascular complications. HbA1c and fasting glucose 
      decreased significantly at the 0.5-year visit and nearly plateaued thereafter in 
      both groups. CONCLUSIONS: Alogliptin as a representative of DPP-4 inhibitors was 
      safe and durably efficacious when used alone or with other OHAs for patients with 
      type 2 diabetes in the real world setting.
CI  - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ueki, Kohjiro
AU  - Ueki K
AUID- ORCID: 0000-0003-1523-8102
AD  - National Center for Global Health and Medicine, Diabetes Research Center, Tokyo, 
      Japan.
FAU - Tanizawa, Yukio
AU  - Tanizawa Y
AD  - Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
FAU - Nakamura, Jiro
AU  - Nakamura J
AD  - Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
FAU - Yamada, Yuichiro
AU  - Yamada Y
AD  - Akita University Graduate School of Medicine, Akita, Japan.
FAU - Inagaki, Nobuya
AU  - Inagaki N
AUID- ORCID: 0000-0001-8261-2593
AD  - Kyoto University Graduate School of Medicine, Kyoto, Japan.
FAU - Watada, Hirotaka
AU  - Watada H
AD  - Juntendo University Graduate School of Medicine, Tokyo, Japan.
FAU - Shimomura, Iichiro
AU  - Shimomura I
AD  - Osaka University Graduate School of Medicine, Osaka, Japan.
FAU - Nishimura, Rimei
AU  - Nishimura R
AD  - Jikei University School of Medicine, Tokyo, Japan.
FAU - Miyoshi, Hideaki
AU  - Miyoshi H
AUID- ORCID: 0000-0002-5909-3243
AD  - Hokkaido University Graduate School of Medicine, Sapporo, Japan.
FAU - Abiko, Atsuko
AU  - Abiko A
AD  - Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
FAU - Katagiri, Hideki
AU  - Katagiri H
AD  - Tohoku University Graduate School of Medicine, Sendai, Japan.
FAU - Hayashi, Michio
AU  - Hayashi M
AD  - Kanto Medical Center NTT EC, Tokyo, Japan.
FAU - Shimada, Akira
AU  - Shimada A
AUID- ORCID: 0000-0002-3954-4983
AD  - Saitama Medical University Faculty of Medicine, Moroyama, Saitama, Japan.
FAU - Naruse, Keiko
AU  - Naruse K
AD  - Aichi Gakuin University School of Dentistry, Nagoya, Japan.
FAU - Fujimoto, Shimpei
AU  - Fujimoto S
AD  - Kochi University Medical School, Nankoku, Kochi, Japan.
FAU - Fujiwara, Masazumi
AU  - Fujiwara M
AD  - Saijo Central Hospital, Saijo, Ehime, Japan.
FAU - Shikata, Kenichi
AU  - Shikata K
AD  - Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, 
      Japan.
FAU - Okada, Yosuke
AU  - Okada Y
AD  - University of Occupational and Environmental Health School of Medicine, 
      Kitakyushu, Fukuoka, Japan.
FAU - Araki, Eiichi
AU  - Araki E
AD  - Kumamoto University, Faculty of Life Sciences, Kumamoto, Japan.
FAU - Yamazaki, Tsutomu
AU  - Yamazaki T
AD  - Graduate School of Medicine, International University of Health and Welfare, 
      Tokyo, Japan.
FAU - Kadowaki, Takashi
AU  - Kadowaki T
AUID- ORCID: 0000-0002-5428-3582
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The 
      University of Tokyo, Tokyo, Japan t-kadowaki@toranomon.kkr.or.jp.
AD  - Toranomon Hospital, Federation of National Public Service Personnel Mutual Aid 
      Associations, Tokyo, Japan.
CN  - J-BRAND Registry Group
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Diabetes Res Care
JT  - BMJ open diabetes research & care
JID - 101641391
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Piperidines)
RN  - 56HH86ZVCT (Uracil)
RN  - JHC049LO86 (alogliptin)
SB  - IM
MH  - Aged
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Japan/epidemiology
MH  - Piperidines
MH  - Prospective Studies
MH  - Registries
MH  - Uracil/analogs & derivatives
PMC - PMC7812112
OTO - NOTNLM
OT  - diabetes mellitus
OT  - dipeptidyl peptidase 4
OT  - registries
OT  - safety
OT  - type 2
COIS- Competing interests: KU reports lecture fees from Takeda, Novo Nordisk, Nippon 
      Boehringer Ingelheim, Mitsubishi Tanabe Pharma, AstraZeneca, MSD, Ono, Sumitomo 
      Dainippon Pharma, Sanofi, and Astellas; research grants from Astellas, Novo 
      Nordisk, Eli Lilly, Nippon Boehringer Ingelheim, Abbott Japan, and MSD; 
      endowments from Takeda, Astellas, Novo Nordisk, Sumitomo Dainippon Pharma, 
      Sanofi, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Daiichi-Sankyo, and Ono. YT 
      reports lecture fees from Takeda, Astellas, AstraZeneca, MSD, Ono, Kyowa Hakko 
      Kirin, Kissei, Kowa, Sanofi Aventis, from Taisho Pharmaceutical, Taisho Pharma, 
      Mitsubishi Tanabe Pharma, Nippon Shinyaku, Bristol-Myers Squibb, Sumitomo 
      Dainippon Pharma, Chugai, Eli Lilly, Nippon Boehringer Ingelheim, and Novo 
      Nordisk; manuscript fees from Kyowa Hakko Kirin; consulting fees from Terumo; 
      research grants from Daiichi-Sankyo and Novo Nordisk; endowments from Astellas, 
      Takeda, Chugai, Sanwa Kagaku, Daiichi-Sankyo, MSD, Kyowa Hakko Kirin, Eisai, 
      Sumitomo Dainippon Pharma, Shionogi, Eli Lilly, Sanofi Aventis, Mitsubishi Tanabe 
      Pharma, Novo Nordisk, Kissei, Nippon Boehringer Ingelheim, Kowa Pharmaceutical, 
      Teijin Pharma, Pfizer, Nihon Pharmaceutical, and Nippon Shinyaku. JN reports 
      lecture fees from Takeda, Astellas, AstraZeneca, MSD, Ono, Kowa Pharmaceutical, 
      Sanofi, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, Terumo, Eli Lilly, Nippon 
      Boehringer Ingelheim, Novartis, Novo Nordisk, Japan Tobacco Inc., Taisho Pharma, 
      Sumitomo Dainippon Pharma, Sanwa Kagaku, Kissei, Mylan, Arkray, Medtronic Japan, 
      Fukuda Denshi, and Abbott Japan; research grants from Kissei, Nippon Boehringer 
      Ingelheim, and Fukuda Colin; endowments from Takeda, Astellas, MSD, Ono, 
      Daiichi-Sankyo, Taisho Pharma, Sumitomo Dainippon Pharma, Mitsubishi Tanabe 
      Pharma, Eli Lilly, Novartis, Novo Nordisk, Japan Tobacco Inc., Otsuka 
      Pharmaceutical, Kaken Pharmaceutical, Kissei, Kyowa Hakko Kirin, Kowa 
      Pharmaceutical, Sanwa Kagaku, Shionogi, Nippon Boehringer Ingelheim, Nippon 
      Becton Dickinson, and Pfizer. YY reports lecture fees from MSD, Novo Nordisk, 
      Ono, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Takeda, Sanofi, and 
      Daiichi-Sankyo; endowments from Ono, Takeda, Mitsubishi Tanabe Pharma, 
      Daiichi-Sankyo, and Sanwa Kagaku. NI reports lecture fees from Takeda, Kowa 
      Pharmaceutical, MSD, Arkray, Astellas, Kissei, Sanofi, Novartis, Novo Nordisk, 
      Bayer, Ono, Kyowa Hakko Kirin, Sumitomo Dainippon Pharma, Daiichi-Sankyo, Eli 
      Lilly, Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Medtronic Japan, 
      Taisho Pharma, Pfizer, Fujifilm Pharma, Saishin Igaku Co., Toyooka Hospital, 
      Terumo, Olympus, Sunstar Foundation, Japan Tabacco Inc., ILSI Japan, University 
      of Occupational and Environmental health, Japan, Japanese Red Cross Wakayama 
      Medical Center, AstraZeneca, Tumura, Chugai, Wakayama Medical University, 
      Hokkaido University, Mainichi Ga Hakken Inc., Boehringer Ingelheim, MSD Life 
      Science Foundation, Taisho Pharmaceutical, and Scohia Pharma; grants from 
      Mitsubishi Tanabe Pharma, Daiichi-Sankyo, AstraZeneca, Sumitomo Dainippon Pharma, 
      Novartis, Novo Nordisk, Astellas, Sanofi, Terumo, Kyowa Hakko Kirin, Taisho 
      Pharma, and Ono; endowments from Takeda, Kissei, Taisho Pharma, Sanofi, 
      Daiichi-Sankyo, Mitsubishi Tanabe Pharma, Japan Tabacco Inc., Kyowa Hakko Kirin, 
      Sumitomo Dainippon Pharma, Astellas, MSD, Ono, Sanwa Kagaku, Eli Lilly, Nippon 
      Boehringer Ingelheim, Novartis, Novo Nordisk, Teijin Pharma, Shionogi, and The 
      Japan China Medical Association. HW reports lecture fees from Takeda, Astellas, 
      Sanofi, Mitsubishi Tanabe Pharma, Novo Nordisk, Kowa Pharmaceutical, AstraZeneca, 
      Novartis, Nippon Boehringer Ingelheim, MSD, Sumitomo Dainippon Pharma, Eli Lilly, 
      Sanwa Kagaku, Ono, Kissei, and Fujifilm Pharma; grants from Kowa Pharmaceutical, 
      Novartis, Sanwa Kagaku, and Eli Lilly; endowments from Takeda, Astellas, Sanofi, 
      Mitsubishi Tanabe Pharma, Novo Nordisk, AstraZeneca, Novartis, Nippon Boehringer 
      Ingelheim, MSD, Sumitomo Dainippon Pharma, Kowa Pharmaceutical, Ono, Kyowa Hakko 
      Kirin, Daiichi-Sankyo, Terumo, Pfizer, Mochida Pharmaceutical, Taisho Pharma, 
      Johnson & Johnson, Sanwa Kagaku, and Kowa. IS reports personal fees from Lotte, 
      Kowa Life Science Foundation, Sunstar Foundation, MSD Life Science Foundation, 
      Kanae Foundation, Senri Life Science Foundation, Fuji Foundation for Protein 
      Research, Japan Cardiovascular Research Foundation, Japan Foundation for Applied 
      Enzymology, Japan Society for the Promotion of Science, NPO Hormon Station, and 
      Kawanishi medical association; lecture fees from Takeda, Japan Pharmacy 
      Laboratory, Asia-Pacific Diabetes and Obesity Study Group, MSD, Astellas, 
      AstraZeneca, Ono, Kyowa Hakko Kirin, Covidien Japan, Kowa Pharmaceutical, Sanofi, 
      The Japan Society of Internal Medicine, Daiichi-Sankyo, Taisho Pharma, Sumitomo 
      Dainippon Pharma, Mitsubishi Tanabe Pharma, Teijin Pharma, Eli Lilly, Nippon 
      Boehringer Ingelheim, Japanese Society for Surgical Metabolism and Nutrition, 
      Novartis, Novo Nordisk, Mochida Pharmaceutical, Rohto Pharmaceutical, Sanwa 
      Kagaku, and Astellas Amgen BioPharma; fees of speakers bureaus from Fuji 
      Foundation for Protein Research; manuscript fees from Iji Publishing, 
      AstraZeneca, Ono, Kyowa Hakko Kirin, Sanwa Kagaku, Eli Lilly, Saishin Igaku-sha, 
      Sentan Igaku-sha, and Medical Review-sha; consulting fees from Takeda, 
      AstraZeneca, MSD, Ono, Kowa Pharmaceutical, Novartis, Novo Nordisk, Sanwa Kagaku, 
      Nippon Boehringer Ingelheim, and Taisho Pharmaceutical; grants from AMED (Japan 
      Agency for Medical Research and Development), National Center for Global Health 
      and Medicine, Fukushima Medical University, Chiba University, Juntendo 
      University, Kowa Pharmaceutical, Rohto Pharmaceutical, Otsuka Pharmaceutical, 
      Sanwa Kagaku, and Immuno-Biological Laboratories; endowments from Takeda, MSD, 
      Astellas, Nippon Becton Dickinson, Sumitomo Dainippon Pharma, Kyowa Hakko Kirin, 
      Terumo, Mitsubishi Tanabe Pharma, Teijin Pharma, Shionogi, Kaken Pharmaceutical, 
      Ono, Novartis, AstraZeneca, Sanofi, Eli Lilly, Daiichi-Sankyo, Kowa 
      Pharmaceutical, Novo Nordisk, The Japan Diabetes Society, Midori Health 
      Management Center, Japan Foundation for Applied Enzymology, MSD Life Science 
      Foundation, Kowa Life Science Foundation, Suzuken Memorial Foundation, Japan 
      Diabetes Foundation, Japan Heart Foundation, Gout Research Foundation, The Uehara 
      Memorial Foundation, Takahashi Industrial and Economic Research Foundation, 
      Soiken Holdings Inc., and Fukumoto Naika Clinic. RN reports lecture fees from 
      Takeda, Sanofi, Medtronic Japan, Nippon Boehringer Ingelheim, Kissei, Novartis, 
      Eli Lilly, Novo Nordisk, MSD, and Astellas; endowments from Japan Diabetes 
      Foundation and Nippon Boehringer Ingelheim. HM reports lecture fees from Takeda, 
      Novo Nordisk, Eli Lilly, Sanofi, Astellas, MSD, Mitsubishi Tanabe Pharma, 
      Sumitomo Dainippon Pharma, Novartis, Ono, Kowa Pharmaceutical, Nippon Boehringer 
      Ingelheim, AstraZeneca, Daiichi-Sankyo, Taisho Pharmaceutical, Teijin Pharma, and 
      Sanwa Kagaku; grants from Astellas and Taisho Pharma; endowments from Takeda, 
      Novo Nordisk, Eli Lilly, Nippon Boehringer Ingelheim, Daiichi-Sankyo, Ono, 
      Sumitomo Dainippon Pharma, Astellas, MSD, Kowa Pharmaceutical, Taisho 
      Pharmaceutical, Teijin Pharma, Sanwa Kagaku, and Kyowa Hakko Kirin. AA reports 
      lecture fees from Takeda, Sanofi, Novo Nordisk, Eli Lilly, Ono, Nippon Boehringer 
      Ingelheim, Kyowa Hakko Kirin, Sanwa Kagaku, Mitsubishi Tanabe Pharma, Astellas, 
      AstraZeneca, MSD, Taisho Pharma, Daiichi-Sankyo, Novartis, Kowa Pharmaceutical, 
      Bayer, Shionogi, Sumitomo Dainippon Pharma, and Fujifilm Pharma; consulting fees 
      from Sanofi and Novo Nordisk; grants from Novo Nordisk and Taisho Pharma. HK 
      reports lecture fees from Takeda, MSD, Novo Nordisk, Daiichi-Sankyo, Astellas, 
      AstraZeneca, Ono, Kyowa Hakko Kirin, Kowa Pharmaceutical, Sanofi, Eli Lilly, 
      Sanwa Kagaku, Taisho Pharma, Sumitomo Dainippon Pharma, Novartis, Mitsubishi 
      Tanabe Pharma, Nippon Boehringer Ingelheim, Bayer, Medtronic Japan, and Alcon 
      Japan; grants from Otsuka Pharmaceutical; endowments from MSD, Eli Lilly, Novo 
      Nordisk, Takeda, Daiichi-Sankyo, Astellas, Sanofi, Novartis, Mitsubishi Tanabe 
      Pharma, Ono, Kyowa Hakko Kirin, Nippon Boehringer Ingelheim, Taisho Pharma, 
      Fujifilm Pharma, Kissei, Nippon Becton Dickinson. MH reports lecture fees from 
      Takeda, Astellas, MSD, Ono, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, 
      Daiichi-Sankyo, Nippon Boehringer Ingelheim, Kowa, Eli Lilly, Novo Nordisk, and 
      Sanofi. AS reports lecture fees from MSD, Eli Lilly, Novo Nordisk, Sanofi, 
      Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Astellas, Ono, and Terumo; 
      endowments from Takeda, MSD, Astellas, Novo Nordisk, Nippon Boehringer Ingelheim, 
      Ono, and Daiichi-Sankyo. KN reports none. SF reports lecture fees from Takeda, 
      Ono, AstraZeneca, Novo Nordisk, MSD, Daiichi-Sankyo, Kyowa Hakko Kirin, Eli 
      Lilly, Kowa, Astellas, Sumitomo Dainippon Pharma, Asahi Kasei Pharma, and Nippon 
      Boehringer Ingelheim; endowments from Takeda, Sanofi, Sumitomo Dainippon Pharma, 
      MSD, Ono, Mitsubishi Tanabe Pharma, Eli Lilly, Novo Nordisk, Shionogi, Nippon 
      Boehringer Ingelheim, Kyowa Hakko Kirin, Taisho Pharma, and Daiichi-Sankyo. MF 
      reports none. KS reports lecture fees from Ono, Novartis, MSD, Astellas, 
      Mitsubishi Tanabe Pharma, AstraZeneca, Sanofi Aventis, Novo Nordisk, Nippon 
      Boehringer Ingelheim, Kyowa Hakko Kirin, Daiichi-Sankyo, and Eli Lilly; 
      manuscript fees from Johnson & Johnson and Kyowa Hakko Kirin; consulting fees 
      from Daiichi-Sankyo; grants from Eli Lilly and Mitsubishi Tanabe Pharma; 
      endowments from Takeda, Mitsubishi Tanabe Pharma, Kyowa Hakko Kirin, MSD, 
      Astellas, Novartis, Ono, Sanofi Aventis, and Chugai. YO reports lecture fees from 
      Takeda, MSD, Eli Lilly, Novartis, Sumitomo Dainippon Pharma, Sanofi, 
      Daiichi-Sankyo, Sanwa Kagaku Kenkyusho, Novo Nordisk, Kissei, Boehringer 
      Ingelheim, AstraZeneca, Astellas, Mitsubishi Tanabe Pharma, Kowa, Bayer, and Ono; 
      grants from Mitsubishi Tanabe Pharma and Kowa. EA reports lecture fees from 
      Takeda, Arkray, Astellas, AstraZeneca, Abbott Japan, Alcon, MSD, Ono, Kyowa 
      Kikaku, Kyowa Hakko Kirin, Kissei, Kowa, Kowa Pharmaceutical, Sanofi, Sanwa 
      Kagaku, Shionogi, Mitsubishi Tanabe Pharma, Daiichi-Sankyo, Taisho 
      Pharmaceutical, Sumitomo Dainippon Pharma, Chugai, Terumo, Eli Lilly, Fujifilm 
      Pharma, Nippon Boehringer Ingelheim, Novartis, Novo Nordisk, Bayer, Pfizer, 
      Medical Review, Medtronic Japan, and MedScape; manuscript fees from Yodosha, Fuji 
      Medical Publishing, and Life science Co; endowments from Takeda, Astellas, MSD, 
      Ono, Kissei, Kyowa Hakko Kirin, Kowa, Sanofi, Shionogi, Taisho Pharmaceutical, 
      Daiichi-Sankyo, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Terumo, Eli 
      Lilly, Nippon Boehringer Ingelheim, Novartis, Novo Nordisk, and Mochida. TY 
      reports lecture fees from Takeda, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, 
      AstraZeneca, Shionogi, and Sumitomo Dainippon Pharma. TK reports lecture fees 
      from Takeda, Astellas, AstraZeneca, MSD, Ono, Eli Lilly, Nippon Boehringer 
      Ingelheim, Novo Nordisk, Mitsubishi Tanabe Pharma, Sanofi, Novartis, Sanwa Kagaku 
      Kenkyusho, Medtronic Japan, Sumitomo Dainippon Pharma, Kyowa Hakko Kirin, Abbott 
      Japan, MedScape Education, Daiichi-Sankyo, and Taisho Pharmaceutical; manuscript 
      fees from Takeda; grants from Takeda, Daiichi-Sankyo, AstraZeneca, Nippon 
      Boehringer Ingelheim, and Eli Lilly; endowments from Takeda, Sumitomo Dainippon 
      Pharma, Astellas, Taisho Pharma, Kyowa Hakko Kirin, Kissei, Novo Nordisk, Sanofi, 
      Ono, Mitsubishi Tanabe Pharma, Daiichi-Sankyo, Kowa Pharmaceutical, MSD, Nippon 
      Boehringer Ingelheim, Terumo, and Asahi Mutual Life Insurance Company.
FIR - Miyoshi, Hideaki
IR  - Miyoshi H
FIR - Abiko, Atsuko
IR  - Abiko A
FIR - Nagai, Sou
IR  - Nagai S
FIR - Yanagisawa, Katsuyuki
IR  - Yanagisawa K
FIR - Kijima, Hiromichi
IR  - Kijima H
FIR - Taneda, Shinji
IR  - Taneda S
FIR - Saitoh, Shigeyuki
IR  - Saitoh S
FIR - Ikeda, Daisuke
IR  - Ikeda D
FIR - Hirano, Fuminori
IR  - Hirano F
FIR - Miura, Takanori
IR  - Miura T
FIR - Miyamoto, Yoshihiro
IR  - Miyamoto Y
FIR - Yoshimura, Haruhiko
IR  - Yoshimura H
FIR - Inoue, Mitsutaka
IR  - Inoue M
FIR - Katoh, Masahiko
IR  - Katoh M
FIR - Nakagaki, Osamu
IR  - Nakagaki O
FIR - Yamamoto, Chiho
IR  - Yamamoto C
FIR - Morikawa, Akitsuki
IR  - Morikawa A
FIR - Yoshida, Kazuhiro
IR  - Yoshida K
FIR - Furukawa, Shin
IR  - Furukawa S
FIR - Koshiya, Takeshi
IR  - Koshiya T
FIR - Sugawara, Hajime
IR  - Sugawara H
FIR - Uchida, Takumi
IR  - Uchida T
FIR - Yamada, Yuichiro
IR  - Yamada Y
FIR - Katagiri, Hideki
IR  - Katagiri H
FIR - Yamaguchi, Hiroshi
IR  - Yamaguchi H
FIR - Takakubo, Noe
IR  - Takakubo N
FIR - Ishigaki, Yasushi
IR  - Ishigaki Y
FIR - Suzuki, Susumu
IR  - Suzuki S
FIR - Shimotomai, Takashi
IR  - Shimotomai T
FIR - Tamasawa, Naoki
IR  - Tamasawa N
FIR - Matsui, Jun
IR  - Matsui J
FIR - Goto, Takashi
IR  - Goto T
FIR - Oizumi, Toshihide
IR  - Oizumi T
FIR - Susa, Shinji
IR  - Susa S
FIR - Daimon, Makoto
IR  - Daimon M
FIR - Matsui, Jun
IR  - Matsui J
FIR - Murakami, Hiroshi
IR  - Murakami H
FIR - Sugawara, Takashi
IR  - Sugawara T
FIR - Akai, Hiroaki
IR  - Akai H
FIR - Matsumoto, Masahiro
IR  - Matsumoto M
FIR - Nakamura, Mari
IR  - Nakamura M
FIR - Ogawa, Yoshiji
IR  - Ogawa Y
FIR - Yokoshima, Takao
IR  - Yokoshima T
FIR - Watanabe, Tsuyoshi
IR  - Watanabe T
FIR - Satoh, Hiroaki
IR  - Satoh H
FIR - Shimabukuro, Michio
IR  - Shimabukuro M
FIR - Tsukamoto, Kazuhisa
IR  - Tsukamoto K
FIR - Kunimi, Motoei
IR  - Kunimi M
FIR - Satoh, Jo
IR  - Satoh J
FIR - Okuyama, Atushi
IR  - Okuyama A
FIR - Ogawa, Kazutaka
IR  - Ogawa K
FIR - Eguchi, Hideyuki
IR  - Eguchi H
FIR - Kimura, Mamoru
IR  - Kimura M
FIR - Kouno, Hiroshi
IR  - Kouno H
FIR - Horikawa, Yohei
IR  - Horikawa Y
FIR - Ikejima, Shin
IR  - Ikejima S
FIR - Saitoh, Masaru
IR  - Saitoh M
FIR - Minami, Naoyoshi
IR  - Minami N
FIR - Sekikawa, Akihiro
IR  - Sekikawa A
FIR - Suzuki, Ryo
IR  - Suzuki R
FIR - Uchida, Toyoyoshi
IR  - Uchida T
FIR - Nishimura, Rimei
IR  - Nishimura R
FIR - Hayashi, Michio
IR  - Hayashi M
FIR - Shimada, Akira
IR  - Shimada A
FIR - Kawai, Toshihide
IR  - Kawai T
FIR - Fujita, Nobuya
IR  - Fujita N
FIR - Tomotsune, Ken
IR  - Tomotsune K
FIR - Yamashita, Shigeo
IR  - Yamashita S
FIR - Naka, Motoji
IR  - Naka M
FIR - Hiyoshi, Toru
IR  - Hiyoshi T
FIR - Nagai, Yoshiyuki
IR  - Nagai Y
FIR - Katoh, Tomotaka
IR  - Katoh T
FIR - Hamano, Kumiko
IR  - Hamano K
FIR - Inukai, Kouichi
IR  - Inukai K
FIR - Kondo, Takuma
IR  - Kondo T
FIR - Tsumura, Kazuhiro
IR  - Tsumura K
FIR - Matsuzawa, Yoko
IR  - Matsuzawa Y
FIR - Mimura, Masahiro
IR  - Mimura M
FIR - Kawasumi, Masahiko
IR  - Kawasumi M
FIR - Takei, Izumi
IR  - Takei I
FIR - Okubo, Yoshiaki
IR  - Okubo Y
FIR - Matsuda, Masafumi
IR  - Matsuda M
FIR - Tatsuno, Ichiro
IR  - Tatsuno I
FIR - Banba, Nobuyuki
IR  - Banba N
FIR - Yamada, Satoru
IR  - Yamada S
FIR - Ando, Akihiko
IR  - Ando A
FIR - Toyoda, Masao
IR  - Toyoda M
FIR - Suzuki, Daisuke
IR  - Suzuki D
FIR - Iijima, Takahiro
IR  - Iijima T
FIR - Mori, Yasumichi
IR  - Mori Y
FIR - Uehara, Yutaka
IR  - Uehara Y
FIR - Satoh, Yoshihiko
IR  - Satoh Y
FIR - Shimano, Hitoshi
IR  - Shimano H
FIR - Isogawa, Akihiro
IR  - Isogawa A
FIR - Yahata, Kazuaki
IR  - Yahata K
FIR - Asoh, Yoshimasa
IR  - Asoh Y
FIR - Kuwabara, Koichiro
IR  - Kuwabara K
FIR - Takizawa, Souichi
IR  - Takizawa S
FIR - Tanaka, Yasushi
IR  - Tanaka Y
FIR - Yokote, Koutaroh
IR  - Yokote K
FIR - Tohgo, Masako
IR  - Tohgo M
FIR - Itoi, Takanobu
IR  - Itoi T
FIR - Miyazaki, Shigeru
IR  - Miyazaki S
FIR - Itoh, Hiroshi
IR  - Itoh H
FIR - Shiba, Teruo
IR  - Shiba T
FIR - Hirose, Takahisa
IR  - Hirose T
FIR - Higa, Mariko
IR  - Higa M
FIR - Yamada, Masanobu
IR  - Yamada M
FIR - Ogawa, Osamu
IR  - Ogawa O
FIR - Kuroki, Masatoshi
IR  - Kuroki M
FIR - Satoh, Shinobu
IR  - Satoh S
FIR - Ujihara, Makoto
IR  - Ujihara M
FIR - Yamanaka, Kenjiroh
IR  - Yamanaka K
FIR - Koyano, Hajime
IR  - Koyano H
FIR - Yamakawa, Tadashi
IR  - Yamakawa T
FIR - Atsumi, Yoshihito
IR  - Atsumi Y
FIR - Takahashi, Kenichiroh
IR  - Takahashi K
FIR - Orime, Kazuki
IR  - Orime K
FIR - Hirano, Tsutomu
IR  - Hirano T
FIR - Morimoto, Jiroh
IR  - Morimoto J
FIR - Awata, Takuya
IR  - Awata T
FIR - Itoh, Takashi
IR  - Itoh T
FIR - Mizuno, Yuzoh
IR  - Mizuno Y
FIR - Yamamoto, Naoyuki
IR  - Yamamoto N
FIR - Miyatake, Han
IR  - Miyatake H
FIR - Yamaguchi, Mina
IR  - Yamaguchi M
FIR - Sone, Hirohito
IR  - Sone H
FIR - Yamane, Kenji
IR  - Yamane K
FIR - Kure, Masahiko
IR  - Kure M
FIR - Kawabe, Satoko
IR  - Kawabe S
FIR - Kakei, Masahumi
IR  - Kakei M
FIR - Yoshida, Masashi
IR  - Yoshida M
FIR - Itoh, Hiroyuki
IR  - Itoh H
FIR - Minami, Nobuaki
IR  - Minami N
FIR - Kobayashi, Kazuki
IR  - Kobayashi K
FIR - Fujino, Yusuke
IR  - Fujino Y
FIR - Shibuya, Makoto
IR  - Shibuya M
FIR - Fukui, Kazuki
IR  - Fukui K
FIR - Hosokawa, Midori
IR  - Hosokawa M
FIR - Nozaki, Isao
IR  - Nozaki I
FIR - Nawa, Chigure
IR  - Nawa C
FIR - Ieiri, Tamio
IR  - Ieiri T
FIR - Watanabe, Takayuki
IR  - Watanabe T
FIR - Katoh, Yoshio
IR  - Katoh Y
FIR - Katabami, Takuyuki
IR  - Katabami T
FIR - Handa, Michiko
IR  - Handa M
FIR - Shimada, Issei
IR  - Shimada I
FIR - Ohya, Kenichi
IR  - Ohya K
FIR - Ogawa, Yoshihiro
IR  - Ogawa Y
FIR - Yoshimoto, Takanobu
IR  - Yoshimoto T
FIR - Nakamura, Jiroh
IR  - Nakamura J
FIR - Naruse, Keiko
IR  - Naruse K
FIR - Sato, Fumihiko
IR  - Sato F
FIR - Sato, Junko
IR  - Sato J
FIR - Okayama, Naotsuka
IR  - Okayama N
FIR - Imaeda, Kenro
IR  - Imaeda K
FIR - Yoshioka, Syuko
IR  - Yoshioka S
FIR - Murakami, Masako
IR  - Murakami M
FIR - Murase, Takashi
IR  - Murase T
FIR - Yamada, Yoshihiko
IR  - Yamada Y
FIR - Yano, Yutaka
IR  - Yano Y
FIR - Sasaki, Hiromitsu
IR  - Sasaki H
FIR - Sumida, Yasuhiro
IR  - Sumida Y
FIR - Ogawa, Kohei
IR  - Ogawa K
FIR - Yonaha, Osamu
IR  - Yonaha O
FIR - Sobajima, Hiroshi
IR  - Sobajima H
FIR - Ito, Mitsuyasu
IR  - Ito M
FIR - Suzuki, Atushi
IR  - Suzuki A
FIR - Ishikawa, Atsuko
IR  - Ishikawa A
FIR - Ichikawa, Takehiko
IR  - Ichikawa T
FIR - Asano, Shogo
IR  - Asano S
FIR - Nakamura, Makoto
IR  - Nakamura M
FIR - Goto, Shinobu
IR  - Goto S
FIR - Hiroya, Sakuma
IR  - Hiroya S
FIR - Murase, Hiroshi
IR  - Murase H
FIR - Ogawa, Shozo
IR  - Ogawa S
FIR - Okamoto, Hideki
IR  - Okamoto H
FIR - Nagai, Kotaro
IR  - Nagai K
FIR - Nagayama, Koji
IR  - Nagayama K
FIR - Yoshida, Masanori
IR  - Yoshida M
FIR - Takahashi, Norio
IR  - Takahashi N
FIR - Takami, Kazuhisa
IR  - Takami K
FIR - Ono, Tsuneo
IR  - Ono T
FIR - Morihiro, Takanobu
IR  - Morihiro T
FIR - Tanaka, Daisuke
IR  - Tanaka D
FIR - Shimomura, Iichiro
IR  - Shimomura I
FIR - Takahara, Noriko
IR  - Takahara N
FIR - Miyata, Satoshi
IR  - Miyata S
FIR - Tsugawa, Mamiko
IR  - Tsugawa M
FIR - Yasuda, Koichiro
IR  - Yasuda K
FIR - Muro, Seiji
IR  - Muro S
FIR - Emoto, Masanori
IR  - Emoto M
FIR - Koya, Daisuke
IR  - Koya D
FIR - Mineo, Ikuo
IR  - Mineo I
FIR - Shiojima, Ichiro
IR  - Shiojima I
FIR - Kurose, Takeshi
IR  - Kurose T
FIR - Akamizu, Takashi
IR  - Akamizu T
FIR - Ohashi, Makoto
IR  - Ohashi M
FIR - Kawabata, Yumiko
IR  - Kawabata Y
FIR - Nishikawa, Mitsushige
IR  - Nishikawa M
FIR - Nomura, Emiko
IR  - Nomura E
FIR - Nishimura, Yasuyuki
IR  - Nishimura Y
FIR - Ono, Yasuhiro
IR  - Ono Y
FIR - Yamamoto, Yasuhisa
IR  - Yamamoto Y
FIR - Naka, Keigo
IR  - Naka K
FIR - Sakaguchi, Kazuhiko
IR  - Sakaguchi K
FIR - Yamamoto, Taizo
IR  - Yamamoto T
FIR - Usuda, Rika
IR  - Usuda R
FIR - Akahori, Hiroshi
IR  - Akahori H
FIR - Kato, Seika
IR  - Kato S
FIR - Otsuka, Akihito
IR  - Otsuka A
FIR - Maegawa, Hiroshi
IR  - Maegawa H
FIR - Yamazaki, Masahiro
IR  - Yamazaki M
FIR - Konya, Hiroyuki
IR  - Konya H
FIR - Umayahara, Yutaka
IR  - Umayahara Y
FIR - Seta, Takashi
IR  - Seta T
FIR - Taki, Hideki
IR  - Taki H
FIR - Sekiya, Masashi
IR  - Sekiya M
FIR - Matsuoka, Naoki
IR  - Matsuoka N
FIR - Mogami, Shinichi
IR  - Mogami S
FIR - Fujii, Sumie
IR  - Fujii S
FIR - Hibuse, Toshiyuki
IR  - Hibuse T
FIR - Tsuji, Shingo
IR  - Tsuji S
FIR - Sumi, Hirofumi
IR  - Sumi H
FIR - Kumeda, Yasuro
IR  - Kumeda Y
FIR - Kogure, Akinori
IR  - Kogure A
FIR - Furukawa, Kenji
IR  - Furukawa K
FIR - Kuroe, Akira
IR  - Kuroe A
FIR - Sawaki, Hideaki
IR  - Sawaki H
FIR - Hibiki, Narihiro
IR  - Hibiki N
FIR - Kitagawa, Yoshihiro
IR  - Kitagawa Y
FIR - Bando, Yukihiro
IR  - Bando Y
FIR - Ono, Akira
IR  - Ono A
FIR - Uenaka, Rikako
IR  - Uenaka R
FIR - Omoto, Seitaro
IR  - Omoto S
FIR - Kita, Yuki
IR  - Kita Y
FIR - Ri, Eiko
IR  - Ri E
FIR - Numaguchi, Ryutaro
IR  - Numaguchi R
FIR - Kawashima, Sachiko
IR  - Kawashima S
FIR - Kisimoto, Ichiro
IR  - Kisimoto I
FIR - Hosoda, Kiminori
IR  - Hosoda K
FIR - Araki, Yoshihiko
IR  - Araki Y
FIR - Arimura, Tetsuroh
IR  - Arimura T
FIR - Hashiramoto, Mitsuru
IR  - Hashiramoto M
FIR - Takeda, Koumei
IR  - Takeda K
FIR - Matsutani, Akira
IR  - Matsutani A
FIR - Shikata, Kenichi
IR  - Shikata K
FIR - Inoue, Yasushi
IR  - Inoue Y
FIR - Sawano, Fumio
IR  - Sawano F
FIR - Kamei, Nozomu
IR  - Kamei N
FIR - Ito, Yasuo
IR  - Ito Y
FIR - Morita, Miwa
IR  - Morita M
FIR - Oda, Yoshiaki
IR  - Oda Y
FIR - Kishimoto, Rui
IR  - Kishimoto R
FIR - Hatao, Katsuhiro
IR  - Hatao K
FIR - Hashiramoto, Mitsuru
IR  - Hashiramoto M
FIR - Mune, Tomoatsu
IR  - Mune T
FIR - Kawasaki, Fumiko
IR  - Kawasaki F
FIR - Teragawa, Hiroki
IR  - Teragawa H
FIR - Yaga, Ken
IR  - Yaga K
FIR - Ishii, Keita
IR  - Ishii K
FIR - Hirata, Kyouji
IR  - Hirata K
FIR - Nakatou, Tatsuaki
IR  - Nakatou T
FIR - Nitta, Yutaka
IR  - Nitta Y
FIR - Fujita, Naoki
IR  - Fujita N
FIR - Yoneda, Masayasu
IR  - Yoneda M
FIR - Tsuru, Masatoshi
IR  - Tsuru M
FIR - Ando, Shinichirou
IR  - Ando S
FIR - Kakiba, Toshiaki
IR  - Kakiba T
FIR - Toyoshige, Michihiro
IR  - Toyoshige M
FIR - Shiwa, Tsuguka
IR  - Shiwa T
FIR - Fujiwara, Masazumi
IR  - Fujiwara M
FIR - Miyaoka, Hiroaki
IR  - Miyaoka H
FIR - Imachi, Hitomi
IR  - Imachi H
FIR - Shintani, Yasumi
IR  - Shintani Y
FIR - Sakai, Takenori
IR  - Sakai T
FIR - Niiya, Tetsuji
IR  - Niiya T
FIR - Fujimoto, Shinpei
IR  - Fujimoto S
FIR - Minami, Hisaka
IR  - Minami H
FIR - Noma, Yoshihiko
IR  - Noma Y
FIR - Tamaru, Masaaki
IR  - Tamaru M
FIR - Sayou, Yoshitaka
IR  - Sayou Y
FIR - Oyama, Tomoyo
IR  - Oyama T
FIR - Torisu, Masamoto
IR  - Torisu M
FIR - Fujinaka, Yuichi
IR  - Fujinaka Y
FIR - Kumon, Yoshitaka
IR  - Kumon Y
FIR - Miyauchi, Shozo
IR  - Miyauchi S
FIR - Osawa, Haruhiko
IR  - Osawa H
FIR - Onji, Morikazu
IR  - Onji M
FIR - Nakamura, Toru
IR  - Nakamura T
FIR - Hiasa, Yoichi
IR  - Hiasa Y
FIR - Okada, Yousuke
IR  - Okada Y
FIR - Yanase, Toshihiko
IR  - Yanase T
FIR - Nishida, Kenro
IR  - Nishida K
FIR - Nakamura, Syuji
IR  - Nakamura S
FIR - Doi, Takashi
IR  - Doi T
FIR - Kobayashi, Kunihisa
IR  - Kobayashi K
FIR - Wada, Nobuhiko
IR  - Wada N
FIR - Higa, Moritake
IR  - Higa M
FIR - Matsushita, Koji
IR  - Matsushita K
FIR - Nishio, Yoshihiko
IR  - Nishio Y
FIR - Fujimoto, Ryoji
IR  - Fujimoto R
FIR - Kihara, Yasuyuki
IR  - Kihara Y
FIR - Mine, Shinichiro
IR  - Mine S
FIR - Arao, Tadashi
IR  - Arao T
FIR - Tasaki, Hiromi
IR  - Tasaki H
FIR - Matsuo, Yasuto
IR  - Matsuo Y
FIR - Matsuda, Hirofumi
IR  - Matsuda H
FIR - Uriu, Kohei
IR  - Uriu K
FIR - Kobayashi, Masakazu
IR  - Kobayashi M
FIR - Kanda, Kazuko
IR  - Kanda K
FIR - Ibaraki, Kazuo
IR  - Ibaraki K
FIR - Kaku, Yoshio
IR  - Kaku Y
FIR - Takaki, Yasuhiro
IR  - Takaki Y
FIR - Hazekawa, Iwaho
IR  - Hazekawa I
FIR - Ebihara, Kenji
IR  - Ebihara K
FIR - Watanabe, Eiichiro
IR  - Watanabe E
FIR - Sakurada, Iku
IR  - Sakurada I
FIR - Muraishi, Kazuhisa
IR  - Muraishi K
FIR - Oshige, Tamami
IR  - Oshige T
FIR - Yasuda, Junichi
IR  - Yasuda J
FIR - Iguchi, Toyoshi
IR  - Iguchi T
FIR - Sonoda, Noriyuki
IR  - Sonoda N
FIR - Adachi, Masahiro
IR  - Adachi M
FIR - Ichino, Isao
IR  - Ichino I
FIR - Horiuchi, Yuko
IR  - Horiuchi Y
FIR - Nakamura, Udai
IR  - Nakamura U
FIR - Uekihara, Souichi
IR  - Uekihara S
FIR - Morimitsu, Shingo
IR  - Morimitsu S
FIR - Nakazawa, Mitsuhiro
IR  - Nakazawa M
FIR - Seguchi, Tadashi
IR  - Seguchi T
FIR - Kaneko, Kengo
IR  - Kaneko K
FIR - Ono, Yasuhiro
IR  - Ono Y
EDAT- 2021/01/15 06:00
MHDA- 2021/07/01 06:00
PMCR- 2021/01/13
CRDT- 2021/01/14 05:34
PHST- 2020/07/23 00:00 [received]
PHST- 2020/11/15 00:00 [revised]
PHST- 2020/12/05 00:00 [accepted]
PHST- 2021/01/14 05:34 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
PHST- 2021/01/13 00:00 [pmc-release]
AID - 9/1/e001787 [pii]
AID - bmjdrc-2020-001787 [pii]
AID - 10.1136/bmjdrc-2020-001787 [doi]
PST - ppublish
SO  - BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 
      10.1136/bmjdrc-2020-001787.